Pharma News: Intermune, Gilead

Market News Video
December 17, 2010 AT 12:34 PM
InterMune (ITMN) shares are surging Friday after an advisory committee to European regulators gave a positive opinion recommending approval of its drug Esbriet. The drug is a treatment for idiopathic pulmonary fibrosis, a progressive and fatal lung disease.